ab-2100
Cell therapyexperimentalBi-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 26, 2024 (NCT06245915)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
- Carbonic anhydrase IXImmunity, passive
CA9 immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06245915 | Phase 1/Phase 2 (Phase 2) | Feb 26, 2024 | Arsenal Biosciences, Arsenal Biosciences, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arsenal Biosciences | For profit | 1 | 0 | 1 | 2024 |
| Arsenal Biosciences, Inc. | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1